UVI5008

UVI5008 is a first-in-class, small molecule "epi-inhibitor" that acts as a reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK) while simultaneously targeting epigenetic regulators, specifically histone deacetylases (HDACs) and sirtuins (SIRT1 and SIRT2). This multi-target approach is designed to address therapeutic challenges in B-cell malignancies, such as chronic lymphocytic leukemia (CLL), particularly in cases where resistance to covalent BTK inhibitors has developed due to mutations like BTK C481S. By modulating both the B-cell receptor signaling pathway and the epigenetic landscape, UVI5008 induces cell cycle arrest and apoptosis in malignant B-cells, offering a potential strategy to overcome suboptimal long-term outcomes associated with single-target inhibitors.